{"entity":{"id":"nct03876769","kind":"trial","name":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","aka":[],"tldr":"A phase 2 trial of Tisagenlecleucel in acute lymphoblastic leukaemia, run by Novartis Pharmaceuticals, active and no longer recruiting.","summary":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients is a phase 2 interventional study registered as NCT03876769 by Novartis Pharmaceuticals, with 121 participants enrolled, started 2019-06-24 and due to reach its primary completion in 2027-10-19. Interventions recorded: CTL019.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03876769","url":"https://clinicaltrials.gov/study/NCT03876769"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia","all-paediatric-high-risk"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":["tisagenlecleucel"],"companies":["novartis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03876769","phase":"2","setting":"A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy","sponsor":"Novartis Pharmaceuticals","participation":[{"nct":"NCT03876769","source":"https://clinicaltrials.gov/study/NCT03876769","fetchedAt":"2026-10-07T16:53:10.205Z","studySha256":"5f03d321811cb0520cea8cedbb567d247d13302112659e6f85fe37ed5a43de02","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-08-19","leadSponsor":"Novartis Pharmaceuticals","collaboratorCount":1,"minimumAge":"1 Year","maximumAge":"25 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":121,"enrolmentType":"ACTUAL","siteCount":43,"recruitingSiteCount":0,"countries":["Belgium","Canada","Denmark","France","Italy","Netherlands","Norway","Spain","Sweden","United Kingdom","United States"]}],"started":"2019-06-24","startedType":"actual","enrolled":121,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03876769/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"all-paediatric-high-risk","kind":"cancer","name":"High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL)","route":"/cancers/all-paediatric-high-risk/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"drug":[{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}]}}